COMPANIES When Haruo Naito, chief executive of Eisai, the Japanese pharmaceutical company, signalled his continued interest in western markets by inaugurating his company's European headquarters in the UK last month, his mind was already elsewhere.
"We have already finished our investments in all major areas in the US and Europe," he says. "Now we are thinking about new areas. We are very interested in emerging markets, especially China, India, the Middle East, Turkey and north Africa."
